Armata Pharmaceuticals Future Growth
Future criteria checks 0/6
Armata Pharmaceuticals's earnings are forecast to decline at 52.2% per annum while its annual revenue is expected to grow at 0.3% per year. EPS is expected to decline by 42% per annum.
Key information
-52.2%
Earnings growth rate
-42.0%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 0.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 6 | -69 | N/A | N/A | 1 |
| 12/31/2024 | 6 | -35 | N/A | N/A | 1 |
| 9/30/2024 | 5 | -41 | -42 | -38 | N/A |
| 6/30/2024 | 4 | -67 | -46 | -39 | N/A |
| 3/31/2024 | 5 | -80 | -47 | -40 | N/A |
| 12/31/2023 | 5 | -69 | -56 | -47 | N/A |
| 9/30/2023 | 4 | -60 | -55 | -50 | N/A |
| 6/30/2023 | 4 | -37 | -54 | -50 | N/A |
| 3/31/2023 | 5 | -43 | -51 | -47 | N/A |
| 12/31/2022 | 6 | -37 | -35 | -32 | N/A |
| 9/30/2022 | 5 | -33 | -33 | -31 | N/A |
| 6/30/2022 | 5 | -29 | -27 | -25 | N/A |
| 3/31/2022 | 5 | -26 | -23 | -22 | N/A |
| 12/31/2021 | 4 | -23 | -25 | -24 | N/A |
| 9/30/2021 | 4 | -24 | -23 | -21 | N/A |
| 6/30/2021 | 3 | -24 | -21 | -20 | N/A |
| 3/31/2021 | 2 | -23 | -21 | -20 | N/A |
| 12/31/2020 | 1 | -22 | -19 | -18 | N/A |
| 9/30/2020 | 0 | -20 | -15 | -15 | N/A |
| 6/30/2020 | 0 | -21 | -16 | -15 | N/A |
| 3/31/2020 | N/A | -21 | -18 | -17 | N/A |
| 12/31/2019 | N/A | -19 | -16 | -16 | N/A |
| 9/30/2019 | N/A | -16 | -17 | -16 | N/A |
| 6/30/2019 | N/A | -12 | -14 | -14 | N/A |
| 3/31/2019 | N/A | -11 | -11 | -10 | N/A |
| 12/31/2018 | N/A | -17 | -12 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARMP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARMP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARMP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARMP's revenue (0.3% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: ARMP's revenue (0.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARMP's Return on Equity is forecast to be high in 3 years time